Ablexis, LLC

Quality Assistance S.A. is a leading European Contract Research Organisation providing the pharmaceutical industry with all the analytical services required by EMA and FDA regulations for the development and marketing of innovative human medicinal products.

We assist our clients from candidate selection, through non-clinical and clinical studies, to marketing authorisation, using our state-of-the-art, product-dedicated expertise in analytical sciences.

For each customer and each project, we design customised solutions, define analytical protocols, develop and validate specific new analytical methods and perform characterisation, stability, pharmacokinetic, biomarker and immunogenicity studies as well as batch release testing, in order to evaluate the Quality, Safety and Efficacy of the given drugs.

Quality Assistance S.A. is an expert for the development of:
- Biologics (monoclonal antibodies, ADCs, proteins)
- New Chemical Entities, oligonucleotides, peptides
- Nanomedicine products
- Vaccines
- Cell-Based and Gene Therapy Medicinal Products

The company holds a unique position on the market with:
All its laboratories on one site (Donstiennes, Belgium)
- Bioanalysis (PK/TK/Immuno)
- Bioassays
- Biochemistry
- Chromatography
- Elemental Impurities
- Mass Spectrometry
- Microbiology
- Molecular Biology
- Protein Characterisation
200 highly qualified professionals
more than 35 years’ expertise at the forefront of analytical sciences.

Our core competencies are:
QUALITY (CMC)
- Development and validation of analytical methods
- Characterisation
- Stability studies
- Batch (release) testing
SAFETY/EFFICACY (Bioanalysis)
- Development and validation of bioanalytical methods
- PK/TK studies
- Immunogenicity studies
- Biomarker studies

The Quality Assistance environment is GMP, GLP and GCLP/GCP compliant.

Visit www.quality-assistance.com for more information

TGA BioServices, an Absorption Systems'​ Company, is an FDA inspected contract research laboratory providing the Pharmaceutical, Biotechnology and Research communities a comprehensive range of laboratory services in support of research and clinical studies. We offer the client a complete package of customized testing systems utilized in preclinical through Phase IV studies, all in compliance with cGLP and cGMP requirements.

We specialize in the development and validation of immunoassay systems for the detection of target molecules, antibody responses and quantification in total compliance with QA and cGMP standards.

TGA BioServices also offers in vivo mouse studies for the optimization of vaccine immunization schedules, dosing, adjuvant screening, immunogenicity testing for the release and stability of bulk and finished clinical product, as well as complete antibody development programs. Furthermore, we offer Guinea pig dermal sensitization testing for the identification of contact allergens. All programs are supervised by an in-house Institutional Animal Care and Use Committee (IACUC), while the facility is USDA registered and AAALAC accredited.

Other services provided include FACScan cell labeling studies, tissue culture, endotoxin testing, basic R&D activities, sample storage, specimen collection kits with on-site training, data management, protocol generation (SOP), database/statistical analysis and consultation. TGA BioServices has the credentials your project is searching for.

Applied StemCell Inc. (ASC) is a fast growing biotechnology company headquartered in Milpitas, California. Our goal is to advance gene-editing and stem cell innovation for biomedical research and the biotechnology industry. After years of research and development, ASC is proud to offer an optimized series of tools for basic research study, drug discovery, bio-processing, bio-production and preclinical applications.
We are currently focusing on three areas: (1) cell line generation for bio-production and bioassays (2) patient-relevant cell models for personalized medicine and (3) physiologically predictive animal models of human diseases. We are striving to improve and expand our technologies and product lines to meet the increasing requirements of the biomedical community.

• Stem Cells & Cell Line Models
• Mouse Model Generation
• AAV Potency Assay
• Antibody Discovery & Screening
• Bioproduction
• Regenerative Medicine
• Pre-IND Filing Consultation

Using our TARGATT™ technology, a gene-of-interest can be specifically inserted at a well-characterized, transcriptionally active locus in the genome with guaranteed transgene expression. This site-specific Knock-in technology has been first established in mouse models, and we have successfully applied it to human cell lines. We are moving forward to various projects that will combine the CRISPR/Cas9 technology and TARGATT™ for highly specified transgene expression.

For patent licensing, business development, and investment inquiries, please contact us at info@appliedstemcell.com.

Caltag Medsystems (CML) has Four Business Divisions:

1. Distribution of Bioscience and Biomedical reagents and kits to the European markets. Key customer groups are Universities, Hospitals, Pharmaceutical Companies, Biotechnology Companies, Private Laboratories. Caltag Medsystems represents over 50 overseas manufacturers from all quarters of the globe. We are looking for new suppliers who fit with our product portfolio and business strategy.
The Cell Culture section of our portfolio includes human and animal primary cells, stem cells, cell lines and media, skin, healthy & diseased human biological materials, angiogenesis models and transfection reagents. Sample types include blood, plasma, serum, bone marrow, CSF, urine, synovial fluid and many more, and are available as matched samples where needed. We supply reagents for the detection of a wide range of different disease biomarkers, together with primary cells and tissue from 26 different cell systems in the human body. Our human biological materials range is extensive, encompassing a wide range of sample types from normal and diseased individuals.
ELISA Kits, Antibodies, Biochemicals and Small Molecules. We provide over 18,000 ELISA kits across a wide range of disease biomarkers including those for apoptosis, cardiovascular, infection and immunity, cytokine and metabolism research and many more. Antibodies, proteins and controls are also available individually.

2. Cytomark Division (www.cytomark.co.uk) - manufacturer of TransFix for stabilisation of whole blood, cerebrospinal fluid, bone marrow and biopsy samples.

3. Cellworks Division (www.cellworks.co.uk) - manufacturer of primary cell models, primary cells, medium and other primary cell reagents. The Cellworks Division is looking for distributors in countries not already represented on our website.

4. Laboratory Services - CRO laboratory services such as Cell Expansion, Flow Cytometry and Angiogenesis service.

CellMosaic®, Inc. is an innovator and leader in bioconjugation and crosslinking technologies. The company was established in 2008 by Dr. Huang, a technological entrepreneur with profound interest and experience in the conjugation field. Since 2008, CellMosaic® has spent a lot of research effort on developing advanced conjugation processes that involve controlled, site-specific, or single labeling methods. These processes can generate single ratio conjugates with greater than 90% purity. We have built a successful custom conjugation service business based on these processes and delivered more than 150 projects and 100 unique conjugates (as of Apr. 2017) for our customers covering a variety of compounds, including proteins, antibodies, peptides, oligos, enzymes, and chemotherapeutic agents. Recently, CellMosaic started to commercialize personalized™ conjugation kits (PerKit™) based on these conjugation processes. Customers can use these kits in house to prepare conjugates with similar high quality as we do at CellMosaic.
Over the years, CellMosaic® has also pioneered the concept of utilizing sugar alcohol (SA) monomers to chemically assemble a new type of crosslinking reagents and polymer carriers, called AqueaTether™ (AqT™), for conjugation and drug delivery. Several other key technologies have also been developed at CellMosaic®, including oxLink™ and sxLink™ technologies for studying protein–protein interactions, and NeIon™ technologies for detecting and quantitating trace amounts of analytes of interest by Mass Spectrometry. Currently, we are developing products using these technologies for R&D usage.
One of the main goals of developing AqT™ linkers and polymers is for drug conjugation and delivery. Please visit www.aqttherapeutics.com to learn more about these applications. Customers who wish to develop their own proprietary therapeutics based on AqT linkers and polymers are encouraged to contact us for how to access these technologies.